Why is closer monitoring of warfarin or cyclosporine needed when blinatumomab treatment begins?

Starting blinatumomab (Blincyto) causes transient cytokine release during the first days that may suppress CYP450 enzymes, requiring monitoring for warfarin adverse effects or cyclosporine concentrations because these medicines have narrow therapeutic indices, with dose adjustment as needed.